This Pilot research is being done to study the safety and feasibility of implanting and retrieving a microdevice that releases microdoses of 19 specific drugs or drug combinations as a possible tool to evaluate the effectiveness of several cancer drugs against metastatic renal cell carcinoma (RCC). The drugs participants receive will include medications currently used as standard-of-care treatment for metastatic RCC as well as medications currently approved in other cancer types that are under investigation for treatment of RCC.~This study involves planting 1 to 6 microdevices, each small enough to fit inside the tip of a needle, into a tumor. The microdevices will release microdoses of cancer drugs via passive diffusion. The drugs will only penetrate the local tumor tissues.~After approximately 3 days, the microdevices and small regions of surrounding tissues will be removed and analyzed.~The research study procedures include screening for eligibility, study imaging and evaluations, blood collections, tumor biopsies, and follow up visits.~The U.S. Food and Drug Administration (FDA) has not approved the microdevice as a treatment for any disease.~The drugs being used have been FDA-approved for the treatment of cancers.~Participation in this research study is expected to last up to 4 months.~It is expected that about 5 people will take part in this research study.
This research is being done to study the safety and feasibility of implanting and retrieving a microdevice that releases microdoses of 19 specific drugs or drug combinations as a possible tool to evaluate the effectiveness of several cancer drugs against metastatic renal cell carcinoma (RCC).~The name of the intervention(s) involved in this study are:~Implantable Microdevice (IMD)~Surgery (excision of tumor)~Drugs used in this study will only include drugs already used as standard of care for the treatment of metastatic renal cell carcinoma (RCC)